^
    Back
    Association details:
    Biomarker:PDGFRA mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Front Immunol
    Title:

    TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer

    Published date:
    09/17/2021
    Excerpt:
    In the primary sample cohort, the top six upregulated genes (ZPAHPN: ZFHX3, PIK3CA, ARID2, HGF, PDGFRA, and NTRK3) and the bottom downregulated gene (KEAP1) were selected as combined predictors for screening responders from non-responders. The results indicated that patients harboring ZPAHPN(+) received more OS benefits than those harboring ZPAHAN(−) or KEAP1(+)...
    DOI:
    https://doi.org/10.3389/fimmu.2021.732125
    Test:
    MSK-IMPACT